David Horrobin Bibliography
Bennett, C.N. and Horrobin, D.F.
The relationship between chromosome sites in schizophrenia and in phospholipid metabolism
Presented at: 11th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, 24th February-1 March 2002.

Bennett, C.N. and Horrobin, D.F.
The relationship between chromosome sites in schizophrenia and in phospholipid metabolism [poster]
Scizophr Res 2002; 53: 79.

Hornych, A.; Oravec, S.; Girault, F.; Forette, B.; Horrobin, D.F.
The effect of gamma-linolenic acid on plasma and membrane lipids and renal prostaglandin synthesis in older subjects
Bratislavske Lekarske Listy 2002; 103(3): 101-7.

Horrobin, D.F.
Peer review of statistics in medical research. Rationale for requiring power calculations is needed [letter]
Br Med J 2002; 325(7362): 491.
(Full text)  

Horrobin, D.F.
Statistics: peer review and ethical review of power calculations [letter]
Br Med J eletters, http://bmj.com/cgi/eletters/324/7348/1271#22692 2002.
(Full text)  

Horrobin, D.F.
Faulty nutrition may compromise schizophrenia patients
Cerebrum 2002; 4: 116-7.

Horrobin, D.F.
Evidence-based medicine and the need for non-commercial clinical research directed towards therapeutic innovation. [review]
Exp Biol Med 2002; 227(7): 435-7.
(Full text)  

Horrobin, D.F.
Cardiovascular disease, affective disorders and impaired fatty acid and phospholipid metabolism
In: Chiu, E.; Ames, D.; Katona, C. (eds.) Vascular disease and affective disorders. Martin Dunitz, London 2002: 75-94.

Horrobin, D.F.
The lipid hypothesis of schizophrenia
In: Skinner, E.R. (Ed.) Brain lipids and disorders in biological psychiatry. Elsevier. 2002: 39-52.

Horrobin, D.F.
Food, micronutrients, and psychiatry [editorial]
Int Psychogeriatr 2002; 14(4): 331-4.

Horrobin, D.F.
Nutritional supplementation in schizophrenia
NHS J Healthcare Professionals 2002; 27: 68-9.

Horrobin, D.F.
Eicosapentaenoic acid (EPA): how may it work in affective disorders? (Abstract)
Presented at: Third European Stanley Foundation Conference on Bipolar Disorder, Freibourg, Germany, 12-13th September 2002.

Horrobin, D.F.
Ethyl eicosapentaenoate (E-EPA, LAX-101): a new approach to the treatment of depression
Presented to: International Society for Affective Disorders Conference, Taormina, Sicily, 9-12 March 2002.

Horrobin, D.F.
Omega-3 fatty acid deficits as explanations for the associations between depression and cardiovascular disease
Presented to: International Society for Affective Disorders Conference, Taormina, Sicily, 9-12 March 2002.

Horrobin, D.F.
A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E)
Prog Drug Res 2002; 59: 171-99.

Horrobin, D.F.
Possible mechanisms for low arachidonate levels, enhanced arachidonate oxidation and impaired niacin flushing in schizophrenia [poster]
Scizophr Res 2002; 53: 154.

Horrobin, D.F.
Integration of the dopamine, glutamate, oxidation, phospholipid and neurodevelopmental hypotheses of schizophrenia [poster]
Scizophr Res 2002; 53: 154.

Horrobin, D.F.
Genes for schizophrenia and bipolar disorder as factors in the late stages of human evolution [poster]
Scizophr Res 2002; 53: 82.

Horrobin, D.F.
Effective clinical innovation: an ethical imperative
The Lancet 2002; 359(9320): 1857-8.

Horrobin, D.F.
Effective clinical innovation
The Lancet 2002; 360(9346): 1697-8.

Horrobin, D.F.; Bennett, C.N.; Manku, M.
Phospholipid and fatty acid metabolism in schizophrenia and depression (Abstract)
Presented at: 8th International Congress on Phospholipids, Vienna, 7-10 September, 2002 2002.

Horrobin, D.F.; Jenkins, K.; Bennett, C.N.; Christie,W.W.
Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding
Prostaglandins Leukot Essent Fatty Acids 2002; 66(1): 83-90.

Horrobin, D.F. and Manku, M.
Treatment of depression with ethyl-eicosapentaenoate (Abstract)
Presented at: International Society for the Study of Fatty Acids and Lipids (ISSFAL) 5th Congress, Montreal, Canada, 8 - 11 May 2002; Fatty Acids and Lipids.

Loder, C.; Allawi, J.; Horrobin, D.F.
Treatment of multiple sclerosis with lofepramine, L-phenylalanine and vitamin B(12): mechanism of action and clinical importance: roles of the locus coeruleus and central noradrenergic systems
Med Hypotheses 2002; 59(5): 594-602.

Lonergan, P.E.; Martin, D.S.; Horrobin, D.F.; Lynch, M.A.
Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation
J Biol Chem 2002; 277(23): 20804-11.
(Full text)  (Abstract)

Martin, D.S.; Lonergan, P.E.; Boland, B.; Fogarty, M.P.; Brady, M.; Horrobin, D.F.; Campbell, V.A.; Lynch, M.A.
Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid
J Biol Chem 2002; 277(37): 34239-46.
(Full text)  (Abstract)

Martin, D.S.; Spencer, P.; Horrobin, D.F.; Lynch, M.A.
Long-term potentiation in aged rats is restored when the age-related decrease in polyunsaturated fatty acid concentration is reversed
Prostaglandins Leukot Essent Fatty Acids 2002; 67(2): 121-30.

Peet, M. and Horrobin, D.F.
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs
Arch Gen Psychiatry 2002; 59(10): 913-9.
(Full text)  (Abstract)

Peet, M. and Horrobin, D.F.
A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms
J Psychiatr Res 2002; 36(1): 7-18.

Puri, B.K.; Bydder, G.M.; Counsell, S.J.; Corridan, B.J.; Richardson, A.J.; Hajnal, J.V.; Appel, C.; McKee, H.M.; Vaddadi, K.S.; Horrobin, D.F.
MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment
Neuroreport 2002; 13(1): 123-6.

Puri, B.K.; Counsell, S.J.; Richardson, A.J.; Horrobin, D.F.
Eicosapentaenoic acid in treatment-resistant depression [letter]
Arch Gen Psychiatry 2002; 59(1): 91-2.

Theander, E.; Horrobin, D.F.; Jacobsson, L.T.; Manthorpe, R.
Gammalinolenic acid treatment of fatigue associated with primary Sjogren's syndrome
Scand J Rheumatol 2002; 31(2): 72-9.

All copyrights acknowledged

© Peter Lapinskas 1999-2012 Email Peter Lapinskas Last updated: 3 July 2012

Home      Services      Background      Publications      Resources      Contact